Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Ugandan pediatric study of R21 + RH5.1 + R78C with Matrix-M given with routine EPI vaccines
PACTR202610764919854Phase 1Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Oct 2026
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of R21/Matrix-M, RH5.1, R78C and Matrix M in malaria (8 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of solicited local and systemic adverse events, Occurrence of unsolicited adverse events and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
R21/Matrix-MRH5.1R78CMatrix M
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202610764919854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610764919854.